Saturday 17 October 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 244.2%, EPS grew 66.7% and free cash flow grew 211.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.59
0.14
−2.96%
Follow OABI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '17 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
2.45 | 4.82 | 5.65 | 2.56 | 6.77 | — |
P/S ratio |
11.26 | 13.73 | 18.24 | 5.01 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
6.00 | 6.48 | 5.12 | 5.69 | 2.68 | — |
P/FCF ratio |
0.00 | 0.00 | 886.23 | 0.00 | 0.00 | — |
Beneish M-Score |
(2.40) | (2.24) | (4.43) | (2.21) | — | — |
P/Operating CF |
(37.05) | (93.59) | (68.31) | (41.45) | (175.56) | — |
P/B ratio |
0.79 | 1.26 | 1.98 | 0.87 | 3.53 | — |
Price to Tangible BV |
3.63 | 5.53 | 8.29 | 3.28 | 0.00 | — |
EV/Sales |
8.37 | 11.48 | 15.69 | 3.52 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(4.28) | (7.64) | 228.39 | (57.93) | (145.62) | — |
EV/FCF |
(4.59) | (7.29) | 762.50 | (10.01) | (145.62) | — |
Quick Ratio |
3.78 | 4.29 | 3.93 | 4.56 | 1.04 | — |
Current Ratio |
4.02 | 4.52 | 4.11 | 4.80 | 1.10 | — |
Net Debt/EBITDA |
1.12 | 1.13 | 1.63 | 10.30 | 0.01 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.06 | 0.08 | 0.09 | 0.16 | 0.23 | — |
Operating CF/Net income |
0.56 | 0.64 | (0.05) | 0.16 | 0.21 | — |
Capex/Depreciation |
0.12 | (0.08) | (0.10) | (0.95) | (0.25) | — |
Interest Coverage |
— | — | — | (45.40) | (5,087.00) | — |
| (23.36%) | (20.60%) | (15.43%) | (7.76%) | 0.00% | — | |
| (20.68%) | (17.70%) | (12.71%) | (6.16%) | (17.76%) | — | |
ROIC |
(20.24%) | (20.41%) | (19.06%) | (6.58%) | (9.51%) | — |
Return on Tangible Assets |
(110.70%) | (90.50%) | (56.22%) | (18.78%) | (308.70%) | — |
Average Days of Receivables |
144.51 | 72.91 | 41.07 | 187.14 | 222.02 | — |
Research and Development Expense of Revenue |
255.83% | 208.82% | 165.45% | 81.87% | 112.90% | — |
Selling, General and Administrative Expense of Revenue |
156.51% | 116.48% | 97.51% | 42.15% | 48.77% | — |
Intangible Assets out of Total Assets |
0.70 | 0.68 | 0.64 | 0.60 | 0.85 | 0.00 |
Share Based Compensation of Revenue |
84.77% | 81.46% | 72.65% | 31.01% | 43.36% | — |
Graham Net Nets |
0.15 | 0.08 | 0.06 | 0.15 | (0.06) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(30.81%) | (16.95%) | (8.16%) | (8.15%) | (3.27%) | — |
Free Cash Flow Yield |
(16.18%) | (11.46%) | 0.11% | (7.01%) | (0.69%) | — |
Revenue per Share |
0.16 | 0.26 | 0.34 | 0.69 | 0.42 | — |
Operating CF per Share |
(0.32) | (0.39) | 0.02 | (0.04) | (0.07) | — |
Capex per Share |
0.02 | (0.02) | (0.02) | (0.20) | (0.05) | — |
Free Cash Flow per Share |
(0.30) | (0.41) | 0.01 | (0.24) | (0.12) | — |
Cash per Share |
0.48 | 0.58 | 0.87 | 1.03 | 0.00 | — |
Shareholders Equity per Share |
2.35 | 2.81 | 3.16 | 4.00 | 2.84 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.35 | 2.81 | 3.16 | 4.00 | 2.84 | — |
Free Cash Flow |
(34.02) | (41.54) | 0.70 | (20.75) | (9.74) | — |
Working Capital |
49.09 | 53.05 | 71.79 | 98.93 | 1.97 | — |
Capital Expenditures |
2.44 | (1.87) | (1.64) | (17.17) | (4.07) | — |
Net Current Asset Value |
31.45 | 30.20 | 34.26 | 45.11 | (47.62) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
(0.13) | 0.07 | 0.05 | 0.29 | 0.12 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||
Depreciation/Fixed assets |
2.22 | 1.43 | 0.88 | 0.90 | 2.39 | — |
Cash ROIC |
(10.60%) | (11.97%) | 0.18% | (4.83%) | (4.15%) | — |
Accounts Receivable Turnover |
2.95 | 5.79 | 2.00 | 2.30 | 0.00 | — |
Accounts Payable Turnover |
0.15 | 0.00 | 0.00 | 5.51 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | 0.00 | 0.00 | — |
Average Days of Payables |
2,263.48 | 0.00 | 0.00 | 66.73 | 71.30 | — |
Days of Inventory on Hand |
0.00 | — | — | 0.00 | 0.00 | — |
Average Receivables |
6.33 | 4.56 | 17.07 | 25.71 | — | — |
Average Payables |
2.09 | 3.35 | 3.69 | 2.95 | — | — |
Average Assets |
313.24 | 350.39 | 398.22 | 362.84 | 152.23 | — |
Average Common Equity |
277.32 | 301.10 | 327.98 | 287.84 | — | — |
Columns are period end dates